31 May 2018  
EMA/CHMP/327758/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Briviact 
brivaracetam 
On 31 May 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal 
product Briviact. The marketing authorisation holder for this medicinal product is UCB Pharma S.A. 
The CHMP adopted an extension to the existing indication as follows2: 
”Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or 
without secondary generalisation in adults and, adolescents patients from 16 years of age and 
children from 4 years of age with epilepsy.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment 
report (EPAR), and will be available in all official European Union languages after a decision on this 
change to the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be 
issued 67 days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
  
                                                
